Loading
Bladder and Urothelial Cancer Treatments / Renal Cell Carcinoma Treatment · Journal article
Frontiers in Immunology · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single-case report of a patient with recurrent clear cell RCC who achieved 45 months without radiographic evidence of disease on third-line toripalimab plus axitinib therapy. The authors acknowledge the limited evidence level and explicitly state that conclusions require validation in future studies. No comparative efficacy data or survival curves are provided.
Single case report. One patient with recurrent clear cell renal cell carcinoma, treated with third-line toripalimab combined with axitinib.. Intervention: Toripalimab combined with axitinib (third-line therapy). n = 1.
Patient achieved no radiographic evidence of disease for 45 months on toripalimab combined with axitinib as third-line therapy Overall survival of 14 years from initial diagnosis reported Diagnosis of recurrence was established by imaging findings rather than histopathological confirmation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
While the sustained disease-free interval is noteworthy, a single case cannot support changes in practice or reliably estimate efficacy. Clinicians should treat this as an illustrative observation, not as evidence of efficacy, and await controlled trial data before considering toripalimab–axitinib in routine third-line management.
A single case report with sustained disease response offers an anecdotal observation but lacks the controlled design, comparator, or sample size needed to establish efficacy; the authors explicitly acknowledge limited evidence requiring validation.
As stated by the source record.
Quoted from the source exactly as published.
While the sustained disease-free interval is noteworthy, a single case cannot support changes in practice or reliably estimate efficacy. Clinicians should treat this as an illustrative observation, not as evidence of efficacy, and await controlled trial data before considering toripalimab–axitinib in routine third-line management.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Renal cancer is estimated to have accounted for 2.4% of all incident cancer cases worldwide in 2018. Renal cell carcinoma (RCC) is the most prevalent adult renal cancer, with the clear cell subtype accounting for 75-85% of cases and displaying pronounced genetic and biological heterogeneity. In the presence of metastatic disease, approximately 80% of patients are not expected to survive beyond one year. Immune checkpoint inhibitors targeting the programed death 1 (PD-1)/PD-L1 axis have been demonstrated to elicit durable clinical responses in patients with RCC. Subsequent therapeutic strategies for immunotherapy-naïve clear cell RCC, as recommended in the NCCN Guidelines Version 1.2026, include no preferred options; other recommended regimens encompass axitinib or lenvatinib in combination with pembrolizumab, cabozantinib with or without nivolumab, everolimus, lenvatinib, and nivolumab with or without ipilimumab. Currently, published evidence supporting the use of toripalimab in combination with axitinib as the third-line treatment for recurrent RCC remains limited. Thus, we report a case of recurrent clear cell RCC in which the patient achieved an overall survival of 14 years and sustained no radiographic evidence of disease for 45 months following third-line therapy with toripalimab in combination with axitinib. Based on the findings in this case, toripalimab combined with axitinib may be an option for relapsed clear cell RCC. Nevertheless, several limitations of this case report warrant acknowledgment: The diagnosis of recurrence was established based on imaging findings rather than confirmation via repeat biopsy and histopathological evaluation. As a case report, the level of evidence remains limited, and the reliability of the conclusions requires further validation in future studies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.